Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29966986 | 0.85 | DGAT1 (0.35) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL29662049 | 0.84 | MAPT (0.35) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL15667485 | 0.84 | MAPT (0.35) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL20745940 | 0.83 | MAPT (0.34) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL30595148 | 0.83 | MAPT (0.34) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL20746046 | 0.82 | MAPT (0.34) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL22864282 | 0.81 | F2RL1 (0.32) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL19780125 | 0.81 | DGAT1 (0.32) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL29661952 | 0.81 | F2RL1 (0.32) | DGAT1MAPTATRATRIPF2RL1 | |
| SCHEMBL20745814 | 0.80 | MAPT (0.37) | DGAT1MAPTATRATRIPF2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4562014-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026479-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014146-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK1 | DGAT1 2712/4885MAPT 4075/4885ATR 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.